Ana Lluch

List of Publications by Year
in descending order

175 papers	17,012 citations	31976 53 h-index	14759 127 g-index
181 all docs	181 docs citations	181 times ranked	19786 citing authors

#	Article	IF	Citations
1	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 25-32.	10.7	1,879
2	Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group. Journal of Clinical Oncology, 2005, 23, 4265-4274.	1.6	1,435
3	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, The, 2010, 375, 377-384.	13.7	1,061
4	An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. Cancer Research, 2008, 68, 6084-6091.	0.9	916
5	Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Research, 2009, 69, 4116-4124.	0.9	768
6	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncology, The, 2016, 17, 791-800.	10.7	623
7	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 305, 1873.	7.4	531
8	AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer. Cancer Cell, 2009, 16, 21-32.	16.8	472
9	Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews, 2012, 38, 698-707.	7.7	466
10	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism, 2017, 26, 633-647.e7.	16.2	449
11	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncology, The, 2014, 15, 640-647.	10.7	406
12	Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer. Journal of Clinical Oncology, 2005, 23, 5323-5333.	1.6	334
13	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Npj Breast Cancer, 2021, 7, 1.	5.2	331
14	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer. Journal of Clinical Oncology, 2007, 25, 3399-3406.	1.6	273
15	Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treatment Reviews, 2010, 36, 206-215.	7.7	228
16	Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1594-1600.	1.6	221
17	Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Research, 2010, 12, R40.	5.0	211
18	Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 805-814.	6.3	208

#	Article	IF	Citations
19	Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2474-2481.	1.6	194
20	p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer. Clinical Cancer Research, 2006, 12, 424-431.	7.0	190
21	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Clinical Cancer Research, 2010, 16, 5351-5361.	7.0	185
22	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology, 2015, 26, 1280-1291.	1.2	177
23	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. New England Journal of Medicine, 2010, 363, 2200-2210.	27.0	169
24	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Research, 2017, 77, 2213-2221.	0.9	168
25	NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clinical Cancer Research, 2002, 8, 347-53.	7.0	163
26	Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Research and Treatment, 1999, 56, 67-78.	2.5	156
27	Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Research and Treatment, 2009, 114, 479-484.	2.5	154
28	Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy. Clinical Cancer Research, 2005, 11, 8715-8721.	7.0	146
29	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Research and Treatment, 2010, 119, 145-153.	2.5	137
30	Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. Clinical Cancer Research, 2009, 15, 3654-3662.	7.0	121
31	Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. Journal of Clinical Oncology, 2016, 34, 1584-1593.	1.6	108
32	Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 1753-1760.	1.6	102
33	High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients. Oncologist, 2012, 17, 766-774.	3.7	101
34	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. Journal of Clinical Oncology, 2016, 34, 1601-1610.	1.6	100
35	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. Nature Cell Biology, 2018, 20, 211-221.	10.3	98
36	Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis. Cancer Research, 2015, 75, 284-295.	0.9	92

#	Article	IF	Citations
37	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. Journal of the National Cancer Institute, 2015, 107, djv256.	6.3	90
38	Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Journal of Clinical Oncology, 2020, 38, 203-213.	1.6	87
39	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget, 2015, 6, 4299-4314.	1.8	87
40	NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. Clinical Cancer Research, 2019, 25, 1535-1545.	7.0	86
41	Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clinical Proteomics, 2011, 8, 11.	2.1	85
42	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Research, 2013, 15, R105.	5.0	80
43	High stability of microRNAs in tissue samples of compromised quality. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 765-774.	2.8	78
44	Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer. Cancer Research, 2007, 67, 818-826.	0.9	75
45	Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. Clinical Cancer Research, 2009, 15, 307-314.	7.0	65
46	Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Research, 2012, 14, R138.	5.0	62
47	The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Scientific Reports, 2017, 7, 41309.	3.3	62
48	The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Scientific Reports, 2019, 9, 5316.	3.3	62
49	Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. Clinical Cancer Research, 2017, 23, 7006-7019.	7.0	61
50	Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer. European Journal of Cancer, 2016, 66, 104-113.	2.8	59
51	Deletion of the PER3 Gene on Chromosome 1p36 in Recurrent ER-Positive Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3770-3778.	1.6	57
52	MicroRNA profile in very young women with breast cancer. BMC Cancer, 2014, 14, 529.	2.6	56
53	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. Journal of Clinical Oncology, 2015, 33, 3788-3795.	1.6	56
54	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. PLoS ONE, 2015, 10, e0126096.	2.5	56

#	Article	IF	Citations
55	Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation. Clinical Cancer Research, 2020, 26, 1432-1448.	7.0	54
56	Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Research and Treatment, 2010, 120, 245-251.	2.5	53
57	Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?. Breast, 2011, 20, 548-554.	2.2	53
58	Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. Journal of Clinical Oncology, 2013, 31, 2593-2599.	1.6	52
59	The single-nucleotide polymorphisms +936 C/T VEGF and â˜'710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Research and Treatment, 2012, 133, 769-778.	2.5	50
60	FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth. Nature Communications, 2016, 7, 11199.	12.8	50
61	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. International Journal of Radiation Oncology Biology Physics, 2018, 101, 316-324.	0.8	50
62	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. Journal of Clinical Investigation, 2020, 130, 4871-4887.	8.2	49
63	Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer. Oncologist, 2012, 17, 469-475.	3.7	48
64	Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility. European Journal of Cancer, 2011, 47, 2618-2625.	2.8	46
65	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS ONE, 2015, 10, e0129876.	2.5	45
66	Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). Breast Cancer Research and Treatment, 2012, 132, 843-851.	2.5	43
67	Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i>-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology, 2018, 36, 3134-3143.	1.6	43
68	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. Oncologist, 2019, 24, 603-611.	3.7	43
69	Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors. Critical Reviews in Oncology/Hematology, 2014, 89, 62-72.	4.4	41
70	Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. Critical Reviews in Oncology/Hematology, 2016, 97, 96-106.	4.4	41
71	MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in Southern European populations: Results from a Meta-analysis. European Journal of Cancer, 2012, 48, 2183-2191.	2.8	40
72	A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Clinical Epigenetics, 2019, 11, 33.	4.1	39

#	Article	IF	Citations
73	Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and theor relation to estradiol receptor (ER) status. Clinica Chimica Acta, 1997, 262, 99-119.	1.1	38
74	Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. Breast Cancer Research and Treatment, 2010, 122, 591-600.	2.5	38
75	Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young women. Scientific Reports, 2018, 8, 14373.	3.3	38
76	Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk. European Journal of Cancer, 2014, 50, 3168-3177.	2.8	35
77	The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer. International Journal of Molecular Sciences, 2016, 17, 1298.	4.1	35
78	Oxidative stress in susceptibility to breast cancer: study in Spanish population. BMC Cancer, 2014, 14, 861.	2.6	34
79	Physical activity and breast cancer risk by pathological subtype. Gynecologic Oncology, 2017, 144, 577-585.	1.4	34
80	Final 10-year results of the Breast International Group 2â€"98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. European Journal of Cancer, 2015, 51, 1481-1489.	2.8	32
81	18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. Clinical Cancer Research, 2017, 23, 1432-1441.	7.0	32
82	Genetic variants in PARP1 (rs3219090) and IRF4(rs12203592) genes associated with melanoma susceptibility in a Spanish population. BMC Cancer, 2013, 13, 160.	2.6	31
83	MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer. Journal of Cellular Biochemistry, 2015, 116, 2061-2073.	2.6	31
84	Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. Clinical Cancer Research, 2002, 8, 3863-9.	7.0	29
85	A PAM50-Based Chemoendocrine Score for Hormone Receptorâ€"Positive Breast Cancer with an Intermediate Risk of Relapse. Clinical Cancer Research, 2017, 23, 3035-3044.	7.0	28
86	The natural history of breast carcinoma in patients with â‰¥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy. Cancer, 2005, 104, 229-235.	4.1	27
87	Nitration of cathepsin D enhances its proteolytic activity during mammary gland remodelling after lactation. Biochemical Journal, 2009, 419, 279-288.	3.7	27
88	Epidermal growth factor receptor in human breast cancer: Correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics. European Journal of Cancer & Clinical Oncology, 1990, 26, 283-290.	0.7	26
89	Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity. Journal of the Academy of Nutrition and Dietetics, 2016, 116, 1914-1924.e6.	0.8	26
90	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research, 2018, 24, 2517-2529.	7.0	26

#	Article	IF	Citations
91	Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. European Journal of Cancer, 2014, 50, 2725-2734.	2.8	25
92	High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer. Cancer Immunology Research, 2019, 7, 1280-1292.	3.4	25
93	Doxorubicin and paclitaxel in advanced breast carcinoma. Cancer, 2000, 89, 2169-2175.	4.1	24
94	Associations between Aromatase CYP19 rs10046 Polymorphism and Breast Cancer Risk: From a Case-Control to a Meta-Analysis of 20,098 Subjects. PLoS ONE, 2013, 8, e53902.	2.5	24
95	Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7427.	4.1	24
96	Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer. Molecular Cancer Therapeutics, 2020, 19, 1696-1707.	4.1	24
97	Fulvestrant ('Faslodex'): Clinical experience from the Compassionate Use Programme. Cancer Treatment Reviews, 2005, 31, S10-S16.	7.7	23
98	Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer, 2014, 14, 166.	2.6	23
99	Breast cancer in pregnant patients: A review of the literature. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 230, 222-227.	1.1	23
100	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. Scientific Reports, 2019, 9, 3904.	3.3	23
101	Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED). Breast Cancer Research and Treatment, 1999, 53, 105-112.	2.5	21
102	Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. Cancer Treatment Reviews, 2008, 34, 701-709.	7.7	21
103	rs12512631 on the Group Specific Complement (Vitamin D-Binding Protein GC) Implicated in Melanoma Susceptibility. PLoS ONE, 2013, 8, e59607.	2.5	21
104	Emerging EGFR antagonists for breast cancer. Expert Opinion on Emerging Drugs, 2014, 19, 165-181.	2.4	21
105	Involvement of Different networks in mammary gland involution after the pregnancy/lactation cycle: Implications in breast cancer. IUBMB Life, 2015, 67, 227-238.	3.4	21
106	Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma. British Journal of Cancer, 2016, 115, 322-331.	6.4	21
107	Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Science Advances, 2022, 8, .	10.3	21
108	Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis. Oncologist, 2015, 20, 111-112.	3.7	20

#	ARTICLE	IF	CITATIONS
109	Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 160, 69-77.	2.5	20
110	Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM. Clinica Chimica Acta, 1993, 215, 51-63.	1.1	19
111	Current perspectives of treatment of ductal carcinoma in situ. Cancer Treatment Reviews, 2010, 36, 507-517.	7.7	18
112	A Customized Pigmentation SNP Array Identifies a Novel SNP Associated with Melanoma Predisposition in the SLC45A2 Gene. PLoS ONE, 2011, 6, e19271.	2.5	18
113	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. Journal of Clinical Oncology, 2012, 30, 3444-3447.	1.6	18
114	Genomic profile of breast cancer: costâ€"effectiveness analysis from the Spanish National Healthcare System perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 889-899.	1.4	18
115	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. European Journal of Cancer, 2019, 120, 54-64.	2.8	18
116	Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. Cancer Treatment Reviews, 2007, 33, 474-483.	7.7	16
117	Costâ€"utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 381-391.	1.4	16
118	Acceleration in the DNA methylation age in breast cancer tumours from very young women. Scientific Reports, 2019, 9, 14991.	3.3	16
119	HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Cancers, 2020, 12, 412.	3.7	16
120	The Â«El ÃlamoÂ» project (1990â€"1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. Clinical and Translational Oncology, 2006, 8, 508-518.	2.4	15
121	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clinical and Translational Oncology, 2009, 11, 363-375.	2.4	15
122	Trastuzumab in small tumours and in elderly women. Cancer Treatment Reviews, 2014, 40, 41-47.	7.7	15
123	Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. Cancers, 2021, 13, 2848.	3.7	14
124	Critically short telomeres and toxicity of chemotherapy in early breast cancer. Oncotarget, 2017, 8, 21472-21482.	1.8	14
125	Mechanisms of resistance to hormonal treatment in breast cancer. Clinical and Translational Oncology, 2010, 12, 246-252.	2.4	13
126	Zoledronic acid in the treatment of metastatic breast cancer. Anti-Cancer Drugs, 2014, 25, 1-7.	1.4	13

#	Article	IF	Citations
127	c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 2780-2790.	4.1	13
128	The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer. Cancers, 2020, 12, 1108.	3.7	13
129	Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. American Journal of Cancer Research, 2016, 6, 2661-2678.	1.4	13
130	Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer. Oncologist, 2011, 16, 956-965.	3.7	12
131	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 5096-5108.	7.0	12
132	Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer. Clinica Chimica Acta, 1994, 229, 107-122.	1.1	11
133	Epistatic interaction of Arg72Pro TP53 and â˜710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival. Molecular and Cellular Biochemistry, 2013, 379, 181-190.	3.1	11
134	Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Npj Breast Cancer, 2021, 7, 44.	5.2	11
135	MicroRNAs in Breast Cancer: One More Turn in Regulation. Current Drug Targets, 2016, 17, 1083-1100.	2.1	11
136	Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer. Melanoma Research, 2009, 19, 211-214.	1.2	10
137	Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator. Breast Cancer: Basic and Clinical Research, 2019, 13, 117822341982876.	1.1	10
138	Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. ACS Sensors, 2021, 6, 1022-1029.	7.8	10
139	Fertility and breast cancer: A literature review of counseling, preservation options and outcomes. Critical Reviews in Oncology/Hematology, 2021, 166, 103461.	4.4	10
140	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. Current Cancer Drug Targets, 2016, 16, 415-428.	1.6	10
141	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Frontiers in Oncology, 2019, 9, 303.	2.8	8
142	Impact of mammography screening programme in the breast cancer population of the Region of Valencia (Spain). Clinical and Translational Oncology, 2008, 10, 745-752.	2.4	7
143	An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer. Breast, 2013, 22, 974-979.	2.2	7
144	Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 553-558.	4.9	7

#	Article	IF	Citations
145	A Phase II Study of Sequential Docetaxel Followed by Doxorubicin/Cyclophosphamide as First-Line Chemotherapy For Metastatic Breast Cancer. Clinical Breast Cancer, 2003, 4, 286-291.	2.4	6
146	Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients. International Journal of Molecular Sciences, 2012, 13, 16500-16513.	4.1	5
147	mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. Molecular Cancer Research, 2022, 20, 1108-1121.	3.4	5
148	The Use of Taxanes in the Neoadjuvant Treatment of Breast Cancer: A Review of Randomized Phase II/III Trials. Clinical Breast Cancer, 2007, 7, 764-774.	2.4	4
149	Integrative cluster classification to predict pathological complete response to neoadjuvant chemotherapy in early breast cancer.. Journal of Clinical Oncology, 2018, 36, 579-579.	1.6	4
150	Intratumoral variations in cytoplasmic estrogen receptor levels in breast cancer. Breast Cancer Research and Treatment, 1987, 9, 69-70.	2.5	3
151	Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. Npj Breast Cancer, 2021, 7, 118.	5.2	3
152	Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models. Current Medicinal Chemistry, 2018, 25, 1976-1998.	2.4	3
153	Immunological Landscape of HER-2 Positive Breast Cancer. Cancers, 2022, 14, 3167.	3.7	3
154	Time-to-progression in breast cancer: A stratification model for clinical trials. Breast, 2008, 17, 239-244.	2.2	2
155	Outcome Differences Between Patients With Node-Negative Breast Cancer Classified According to the St. Gallen Risk Categories. Clinical Breast Cancer, 2009, 9, 231-236.	2.4	2
156	Supportive care for patients with early breast cancer. Clinical and Translational Oncology, 2010, 12, 32-42.	2.4	2
157	Current controversies in the management of breast cancer. Clinical and Translational Oncology, 2010, 12, 278-286.	2.4	2
158	Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. Clinical and Translational Oncology, 2008, 10, 552-559.	2.4	1
159	In response: Genomic profile of breast cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 395-397.	1.4	1
160	DNA Methylation in Breast Cancer. , 2016, , 297-312.		1
161	DNA methylation as an epigenetic signature predictive of response to neodjuvant treatment in TNBC patients.. Journal of Clinical Oncology, 2018, 36, e12658-e12658.	1.6	1
162	The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview. Clinical and Translational Oncology, 2022, , 1.	2.4	1

#	Article	IF	Citations
163	Evolution of tumour biology upon progression. Do we know our enemy?. Clinical and Translational Oncology, 2012, 14, 399-400.	2.4	0
164	In Reply to Belkacemi and Tsoutsou. International Journal of Radiation Oncology Biology Physics, 2018, 102, 467-468.	0.8	0
165	miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342097784.	1.1	0
166	Reply to Y. Usui et al. Journal of Clinical Oncology, 2020, 38, 2113-2114.	1.6	0
167	A prognostic miRNA based signature in early-stage HER2-positive breast cancer patients.. Journal of Clinical Oncology, 2021, 39, e12600-e12600.	1.6	0
168	Retrospective analysis of the use of GCSF and its impact on dose-response effect for anthracycline plus taxane-based schedules in early breast cancer.. Journal of Clinical Oncology, 2012, 30, e11523-e11523.	1.6	0
169	Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis.. Journal of Clinical Oncology, 2012, 30, 1074-1074.	1.6	0
170	Thirteen miRNAs involved in the response of breast cancer cells to doxorubicin.. Journal of Clinical Oncology, 2013, 31, e12019-e12019.	1.6	0
171	Abstract 3940: Baseline molecular markers and risk of distant relapse in the NeoSphere study. , 2016, , .		0
172	Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14).. Journal of Clinical Oncology, 2018, 36, 592-592.	1.6	0
173	Abstract 5271: Correlative analysis of RNA biomarkers for adjuvant capecitabine benefit in the CIBOMA/2004-01phase III clinical trial of triple negative breast cancer patients. Cancer Research, 2022, 82, 5271-5271.	0.9	0
174	Role of germline variants in the metastasis of breast carcinomas. Oncotarget, 2022, 13, 843-862.	1.8	0
175	Physiciansâ€™ adherence, attitudes, and perceived barriers to the Mexican breast cancer clinical practice guidelines (BCCPG).. Journal of Clinical Oncology, 2022, 40, e18669-e18669.	1.6	0